重组人血管内皮抑制素联合顺铂胸腔注射治疗非小细胞肺癌合并血性胸腔积液的效果观察  

Effects of recombinant human endostatin combined with intraleural injection of cisplatin on patients with non-small cell lung cancer complicated with blood pleural effusion

作　　者：李树文 Li Shuwen(Department of Thoracic Surgery,Xinzhou People's Hospital,Xinzhou 034000,China)

机构地区：[1]山西省忻州市人民医院胸外科,034000

出　　处：《中国实用医刊》2020年第3期102-104,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨非小细胞肺癌并发血性胸腔积液患者在使用顺铂胸腔注射同时加用重组人血管内皮抑制素治疗的效果。方法选取忻州市人民医院2012年1月至2017年12月收治的非小细胞肺癌并发血性胸腔积液患者40例,按照随机数字表法分为对照组与观察组,每组20例。对照组单用顺铂胸腔注射治疗,观察组加用重组人血管内皮抑制素治疗。对比两组临床总有效率及治疗前后血清肿瘤标志物糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)水平,观察两组不良反应发生情况。结果观察组治疗总有效率为80%(16/20),高于对照组的35%(7/20),P<0.05。治疗前,两组血清肿瘤标志物CA125、CA199、CEA比较差异未见统计学意义(P>0.05);治疗后均有改善,且观察组改善程度优于对照组(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05),但观察组1年生存率[70%(14/20)]高于对照组[35%(7/20)],P<0.05。结论重组人血管内皮抑制素联合顺铂胸腔注射治疗非小细胞肺癌合并血性胸腔积液,可提高其治疗总有效率,改善血清肿瘤标志物水平,且具有较高安全性。Objective To investigate the effects of recombinant human endostatin combined with intraleural injection of cisplatin in the treatment of non-small cell lung cancer complicated with blood pleural effusion.Methods Forty patients with non-small cell lung cancer complicated with bloody pleural effusion treated in Xinzhou People’s Hospital from January 2012 to December 2017 were selected. And they were divided into study group and control group according to the random number table method, with 20 cases in each group. The control group was treated with intrapleural injection of cisplatin, while the observation group was treated with recombinant human endostatin and cisplatin. The total efficacy and serum tumor markers, such as carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) were compared between the two groups.Results The total effective rate of the observation group was 80% (16/20), higher than 35% (7/20) of the control group (P<0.05). Before treatment, there was no significant difference in serum tumor markers (CA125, CA199, CEA) between the two groups (P>0.05). However, the serum tumor markers were improved in the two groups after treatment, and the improvement of the observation group was better than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The 1-year survival rate of the observation group was 70% (14/20), higher than 35% (7/20) of the control group (P<0.05).Conclusions Recombinant human endostatin combined with cisplatin in the treatment of non-small cell lung cancer complicated with blood pleural effusion can improve the total effective rate and levels of serum tumor markers, with high safety.

关 键 词：非小细胞肺癌 血性胸腔积液 顺铂 重组人血管内皮抑制素 胸腔注射 

分 类 号：R734[医药卫生—肿瘤]